
|Videos|December 6, 2017
Dr. Barrientos Discusses Ibrutinib in Elderly Populations With CLL
Author(s)Jacqueline C. Barrientos, MD
Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with CLL.
Advertisement
Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with chronic lymphocytic leukemia (CLL).
The 3-year follow-up of the registration trial of ibrutinib in elderly patients with CLL showed promising response rates, says Barrientos, making it her go-to drug for this population.
Additionally, combinations with ibrutinib are in the pipeline, such as ibrutinib plus obinutuzumab (Gazyva).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































